Collaboration with Eli Lilly and Company to develop bi-specific antibodies, using Zymeworks’ proprietary Azymetric™ platform, against multiple Lilly targets for immunotherapy and other applications. Under the terms of the agreement, Zymeworks has granted Lilly a worldwide license to the Azymetric™ platform to develop and commercialize therapeutic candidates in exchange for up to US $375 million in milestones and other payments, plus tiered sales royalties. In addition, Zymeworks received an initial up-front payment in the form of an equity investment.
Collaboration with Merck to develop bi-specific antibody therapeutics using Zymeworks’ Azymetric™ platform. Under the terms of the original agreement (2011) and the expanded collaboration (2014), Zymeworks has granted Merck, through a subsidiary, a worldwide license to develop and commercialize bi-specific antibodies generated through use of the Azymetric™ platform toward certain therapeutic targets. Both companies will collaborate to advance the technology platform and to progress bi-specific therapeutic antibody candidates in pre-clinical developments with Merck responsible for clinical development and commercialization.
Collaboration to optimize an undisclosed antibody using Zymeworks' ZymeCAD suite of predictive protein engineering tools and XOMA's innovative Targeted Affinity Enhancement (TAE) technology for antibody mutagenesis and optimization.
Collaboration to evaluate the application of Zymeworks' computational biotechnology and predictive protein engineering tools in the context of discovering promising new enzymes for use in DSM’s biocatalytic processes.
Zymeworks and SGI have partnered to make collaborative advancements in high performance scientific computing and research into parallel algorithms for molecular modeling.
If you are interested in exploring partnering opportunities with Zymeworks, please contact us at email@example.com.